team :: sullivan

Dr. Marc Penn is a cardiologist in the Department of Cardiovascular Medicine in the Heart and Vascular Institute of Cleveland Clinic. He is Director of the Bakken Heart-Brain Institute and Director of the Skirball Laboratory of Cardiovascular Cellular Therapeutics. In 2008 he stepped down as Medical Director of the Coronary Intensive Care Unit to become the first director of the Center for Cardiovascular Cell Therapy at the Cleveland Clinic. He also serves as the Associate Director of the Cardiovascular Medicine. Dr. Penn is board certified in Cardiovascular Medicine.

Dr. Penn completed his undergraduate and post graduate work at Case Western Reserve University completing a Ph.D. in Biomedical Engineering. Dr. Penn earned his medical degree from Case Western Reserve University School of Medicine. He completed his Internal Medicine training at University Hospitals of Cleveland and his Cardiovascular Medicine Fellowship at Cleveland Clinic. He joined the professional staff of Cleveland Clinic in July of 2000.

Dr. Penn’s education and training have helped him developing drug delivery systems for the treatment of cardiovascular disease, including studies to optimize gene therapy and stem cell therapy for the regeneration of myocardial tissue from which several patents are pending. Dr. Penn has an academic appointment at Case Western Reserve University in the Department of Biomedical Engineering and the Bioengineering Center at Cleveland State University. He is recipient of the 2000 Joseph Cash Memorial Prize for Clinical Outcomes Research and the 1999 Irvine H. Page Young Investigator award presented by the National American Heart Association, among others.

In 2001, Dr. Penn was named Director of the Experimental Cardiology Laboratory in the Department of Cardiovascular Medicine at the Cleveland Clinic. This laboratory is dedicated to the discovery and implementation of novel drug, cell and gene therapies, and devices to prevent and treat cardiovascular disease.

Dr. Penn has been an invited lecturer at international symposiums and conferences and is author or co-author of numerous published articles, abstracts, book chapters and books on a wide range of topics, from diabetes and lipoprotein oxidation; mechanisms of clot formation in atherosclerotic arteries, optimal management of patients with acute aortic dissection, and stem cell and gene based therapies for acute myocardial infarction and heart failure. He is the Editor or co-Editor of 3 books including Stem Cells and Myocardial Regeneration published by Humana Press.

Dr. Penn is an active inventor, and is named on several patent applications under review, including several in the area of stem cell based therapies for the treatment of chronic heart failure. He is the founder of Juventas Therapeutics, a privately funded regenerative medicine based myocardial therapeutics company founded on intellectual property developed in his laboratory. He is a founder and angel investor in Cour Therapeutics. He is the founding CMO and inventor in Prognostix, Inc, a diagnostic company based on biomarkers associated with coronary artery disease, myocardial infarction and other inflammatory diseases. He is a founder and CSO of Cardionomic, a company exploiting neuromodualtion of the heart to improve outcomes in patients with chronic heart failure. He is an angel investor and CSO for Cour Pharma, a Kalamazoo, MI based company optimizing drug design to minimize cardiovascular sides effects of current and future pharmaceuticals. He served on the Scientific Advisory Board Frantz Medical Ventures (New York City) and a Venture Partner with Oakwood Medical Investors (St. Louis, MO). He received the Innovator of the Year Award from the Cleveland Clinic in 2006. In October of 2008 Dr. Penn became the Senior Medical Director for Emerging Businesses at Cleveland Clinic.